These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis.
    Author: Takase K, Ohno S, Ideguchi H, Uchio E, Takeno M, Ishigatsubo Y.
    Journal: Rheumatol Int; 2011 Feb; 31(2):243-5. PubMed ID: 19816689.
    Abstract:
    Infliximab has demonstrated remarkable effects on controlling uveitis in patients with Behçet's disease (BD). However, there is no way except for discontinuation of infliximab treatment in patients who are intolerant to the agent due to hypersensitivity reactions. We here report successful switching from infliximab to adalimumab in a BD patient. Treatment with infliximab had maintained clinical remission in the patient having refractory ocular lesions to cyclosporine until the patient had experienced repeated infliximab-related infusion reactions. Discontinuation of the therapy led to another ocular attacks immediately. Switching to adalimumab induced clinical remission again. Our experience suggest adalimumab is a safe and effective option for patients having hypersensitivity to infliximab.
    [Abstract] [Full Text] [Related] [New Search]